A decision in the case of UK Anti-Doping (UKAD) against Krzysztof Glowacki has been issued by the National Anti-Doping Panel (NADP).
On 6 April 2023, Mr Glowacki was notified by UKAD that he may have committed Anti-Doping Rule Violations (ADRVs) for Presence of a Prohibited Substance in a Sample taken on 21 January 2023, boldenone, and Use of the same Prohibited Substance. This notification further mentioned that he was provisionally suspended.
On 2 June 2023, UKAD formally issued Mr Glowacki with a Notice of Charge for committing the ADRVs pursuant to Anti-Doping Rules (ADR) Articles 2.1 and 2.2.
The National Anti-Doping Tribunal, comprised of Robert Englehart KC (Chair), Blondel Thompson and Professor Brian Lunn, was appointed to determine this matter.
Mr Glowacki denied ever using illegal doping substances and stated that he never intentionally violated any doping rules. However, he did not provide a full response to the charges other than informing the Tribunal that he denied all violations and that the bout on 21 January 2023 (where he tested positive) was the final one in his career, as he had chosen to not fight again as a professional boxer. In the hearing Mr Glowacki stated, for the first time, that prior to the bout in question he had seriously injured his left hand and was treated with the application of a patch and requested more time to provide medical evidence. The medical evidence submitted was a document from a clinic in Warsaw.
The Tribunal determined that there was unchallenged evidence that Mr Glowacki’s urine Sample contained boldenone, consequently the Tribunal was satisfied that there were ADRVs under ADR articles 2.1 and 2.2. The Tribunal then analysed whether these ADRVs were intentional and concluded that Mr Glowacki did not satisfy the Tribunal given that he only provided a bare denial of ever having ingested any banned drug. Further, the Tribunal established that the medical evidence submitted was of no assistance in establishing how boldenone came to be in Mr Glowacki’s system.
Accordingly, the Tribunal was satisfied that Mr Glowacki had committed the ADRVs pursuant to ADR Article 2.1 and Article 2.2 and imposed a period of Ineligibility of four years. Given that Mr Glowacki had been subject to a Provisional Suspension since 6 April 2023 and there was no evidence that he had not observed the Provisional Suspension, the four year period of Ineligibility was set to run from 6 April 2023 and end at midnight 5 April 2027.
A copy of the full decision can be accessed via the related links tab on the right-hand side.
The National Anti-Doping Panel is the United Kingdom’s independent tribunal responsible for adjudicating anti-doping disputes in sport. It is operated by Sport Resolutions and is entirely independent of UK Anti-Doping who is responsible for investigating, charging, and prosecuting cases before the NADP.